CRBP logo

CRBP
Corbus Pharmaceuticals Holdings Inc

21,456
Mkt Cap
$140.6M
Volume
222,175.00
52W High
$20.56
52W Low
$4.64
PE Ratio
-1.45
CRBP Fundamentals
Price
$7.39
Prev Close
$8.01
Open
$7.98
50D MA
$9.09
Beta
1.36
Avg. Volume
174,058.65
EPS (Annual)
-$3.68
P/B
1.09
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Corbus Pharmaceuticals (NASDAQ:CRBP) COO Ian Hodgson Sells 2,415 Shares
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) COO Ian Hodgson sold 2,415 shares of the business's stock in a transaction that occurred on Tuesday, February 3rd. The stock was...
MarketBeat·15h ago
News Placeholder
More News
News Placeholder
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven analysts that are currently covering the company...
MarketBeat·14d ago
News Placeholder
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Brokerages
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven research firms that are presently covering the stock...
MarketBeat·1mo ago
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Below Fifty Day Moving Average - Should You Sell?
Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Passes Below Fifty Day Moving Average - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal?
Corbus Pharmaceuticals said its Phase 1a study showed CRB-913 was safe and well-tolerated at all doses, with no serious adverse events reported.
Stocktwits·2mo ago
News Placeholder
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Analysts
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat...
MarketBeat·2mo ago
News Placeholder
B. Riley Forecasts Lower Earnings for Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at B. Riley dropped their FY2025 earnings per share estimates for Corbus Pharmaceuticals in a report released...
MarketBeat·2mo ago
News Placeholder
What is B. Riley's Forecast for CRBP FY2029 Earnings?
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at B. Riley issued their FY2029 EPS estimates for Corbus Pharmaceuticals in a research note issued to investors...
MarketBeat·2mo ago
News Placeholder
Research Analysts Issue Forecasts for CRBP Q1 Earnings
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings estimates for Corbus Pharmaceuticals in a research note issued to investors...
MarketBeat·3mo ago
News Placeholder
Royal Bank Of Canada Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00
Royal Bank Of Canada reduced their target price on shares of Corbus Pharmaceuticals from $55.00 to $53.00 and set an "outperform" rating on the stock in a research report on Thursday...
MarketBeat·3mo ago
<
1
2
...
>

Latest CRBP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.